The Future of Lipid-lowering Therapy

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors are revolutionizing low-density lipoprotein (LDL) cholesterol management for atherosclerotic cardiovascular disease (ASCVD).
• Existing therapies inadequately address lipoprotein(a) (Lp(a)) and plasma triglycerides, significant ASCVD risk factors.
• There is a critical need for novel therapeutic strategies targeting these residual risk factors.

Purpose of the Study:

• To review the evidence and rationale for targeting Lp(a) and triglycerides in ASCVD.
• To provide an overview of emerging therapeutic strategies for lowering Lp(a), apolipoprotein C-III, and angiopoietin-like protein 3.
• To summarize recent findings on omega-3 fatty acids (OM3FA) in ASCVD management.

Main Methods:

• Literature review of current evidence and ongoing clinical trials.
• Analysis of the mechanisms of action for novel lipid-lowering agents.
• Synthesis of data on experimental therapies including monoclonal antibodies and antisense oligonucleotides.

Main Results:

• Emerging therapies show promise in targeting Lp(a), apolipoprotein C-III, and angiopoietin-like protein 3.
• Omega-3 fatty acids (OM3FA) present a potential adjunctive therapy for ASCVD.
• The long-term safety and efficacy of these novel agents remain to be established.

Conclusions:

• Targeting Lp(a) and triglycerides represents a significant advancement in ASCVD risk reduction.
• Monoclonal antibodies and antisense oligonucleotides are key experimental modalities requiring further validation.
• Clinical outcome trials are essential to determine the ultimate role of these new therapies in reducing ASCVD risk.